The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US STOCKS-Wall St ends near flat after recent gains; healthcare climbs

Mon, 13th May 2013 20:42

* Core U.S. retail sales rise 0.5 percent in April

* Yum Brands falls as monthly Chinese sales drop

* Indexes: Dow down 0.2 pct, S&P flat, Nasdaq up 0.1 pct

By Caroline Valetkevitch

NEW YORK, May 13 (Reuters) - U.S. stocks ended flat onMonday, pausing after hitting record highs last week, butstrength in healthcare issues helped to keep declines in check.

The S&P 500 healthcare sector climbed 0.7 percentand was the day's best performer.

Shares of Theravance jumped 17.9 percent to $41.20after Irish drugmaker Elan agreed to a $1billion deal to buy 21 percent of the royalties that Theravancereceives from GlaxoSmithKline for itsrespiratory drugs.

The day's flat activity follows a third straight week ofgains on the major indexes, with both the Dow and S&P 500setting record closing highs last week. The S&P 500 remains up14.5 percent for the year so far.

While some analysts argue the long-term trend is stillhigher, many see momentum waning in the near term in the absenceof positive catalysts. Volume has been lighter than average, andvolatility has been low in recent days.

"Intraday volatility has essentially been nonexistent. Ithink it means people are really sitting on the sidelines rightnow seeing which way it's going to go," said Uri Landesman,president of Platinum Partners in New York.

The CBOE Volatility index ended down 0.3 percent.

The Dow Jones industrial average was down 26.81points, or 0.18 percent, at 15,091.68. The Standard & Poor's 500Index was up 0.07 points at 1,633.77. The NasdaqComposite Index was up 2.21 points, or 0.06 percent, at3,438.79.

Among the day's decliners, Yum Brands Inc fell 2percent to $68.92. After the market closed on Friday, the fastfood chain operator posted a steep decline in Chinese Aprilsales.

Helping to limit the market's downside, retail sales rose0.1 percent in April, better than the 0.3 percent drop that hadbeen expected, and returning to growth following a decline inMarch. Excluding autos, gasoline and buildingmaterials, core sales rose 0.5 percent. Retail sales account forabout 30 percent of U.S. consumer spending.

Investors are at odds over whether positive economic datacan help the market rise further, or whether it will spell theend of the Federal Reserve's monetary stimulus, which couldderail the rally, said Joseph Tanious, global market strategistat J.P. Morgan Funds.

Other data showed business inventories were unchanged inMarch for a second straight month, versus expectations of 0.3percent rise, suggesting restocking could help second-quartereconomic growth.

Earnings have been mostly better than expected. With 90percent of the S&P 500 having reported, 67.2 percent ofcompanies have topped earnings expectations, according toThomson Reuters data, even with the average over the past fourquarters. Only 46.9 percent have beaten revenue expectations,below the 52 percent average over the past four quarters.

U.S.-listed shares of Perion Network surged 10.6percent to $13.94 after the Israeli consumer Internet companyposted first-quarter earnings.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.